Alzheimer’s Disease (AD) affects millions of elderly people, many of the patients partially or completely lost the capability to maintain independent daily living [1-3]. Limited progress was made in the past decades in the designing intervention approaches that could effectively delay the progression of the disease. Novel leads are in urgent need. Next Generation DNA sequencing (NGS) technology has been widely used in the basic biomedical research and molecular diagnosis in clinical settings. Few NGS studies in AD were reported, and those reported focused on rare variants from a few genes, such as APP, PSEN1, PSEN2, SORL1, and TREM2 [4-6]. Recently results from some Whole Exome Sequencing (WES) studies with specimens from AD patients were reported, but a general variant landscape is still missing [7-9]. Accumulated variants of these genes only account for the genetics of a small fraction of AD patients. Genome-Wide Association Studies (GWAS) identified several dozen AD associated genes, but most of the associations are weak [10-12]. We performed a WES study with specimens from AD patients, and we identified several dozen novel gene variants. These novel variants could potentially be causative mutations for AD or variants in association with AD.
Keywords:
Published on: May 12, 2020 Pages: 1-4
Full Text PDF
Full Text HTML
DOI: 10.17352/aadc.000009
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."